Detalles de la búsqueda
1.
Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes.
Antimicrob Agents Chemother
; 65(5)2023 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33649107
2.
Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence In Vitro.
Antimicrob Agents Chemother
; 66(5): e0203821, 2022 05 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-35389236
3.
Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants.
J Antimicrob Chemother
; 76(8): 2153-2157, 2021 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33880558
4.
Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks.
Antimicrob Agents Chemother
; 63(5)2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30803969
5.
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
J Antimicrob Chemother
; 74(12): 3555-3564, 2019 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31430369
6.
Antiviral activity of HIV-1 integrase strand-transfer inhibitors against mutants with integrase resistance-associated mutations and their frequency in treatment-naïve individuals.
J Med Virol
; 91(12): 2188-2194, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31389026
7.
Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions.
Antimicrob Agents Chemother
; 60(2): 757-65, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26574015
8.
Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.
Antimicrob Agents Chemother
; 60(12): 7086-7097, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27645238
9.
Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study.
HIV Clin Trials
; 17(1): 29-37, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26899540
10.
A cell-based strategy to assess intrinsic inhibition efficiencies of HIV-1 reverse transcriptase inhibitors.
Antimicrob Agents Chemother
; 59(2): 838-48, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25403670
11.
Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations.
Antimicrob Agents Chemother
; 59(6): 3441-9, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25824231
12.
96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
HIV Clin Trials
; 16(1): 30-8, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25777187
13.
The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro.
Antimicrob Agents Chemother
; 58(10): 6145-50, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25092710
14.
Erratum to: Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
J Antimicrob Chemother
; 74(12): 3646-3647, 2019 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31562501
15.
Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.
HIV Clin Trials
; 15(5): 218-30, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25350960
16.
Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.
Antimicrob Agents Chemother
; 57(6): 2654-63, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23529738
17.
Inhibition of 2',5'-oligoadenylate synthetase expression and function by the human cytomegalovirus ORF94 gene product.
J Virol
; 85(11): 5696-700, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21450824
18.
Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.
J Acquir Immune Defic Syndr
; 89(4): 433-440, 2022 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34897227
19.
High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I.
AIDS
; 36(11): 1511-1520, 2022 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35466963
20.
Mechanism of resistance to GS-9148 conferred by the Q151L mutation in HIV-1 reverse transcriptase.
Antimicrob Agents Chemother
; 55(6): 2662-9, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21402840